GlassScriptPhysician profile
Kathy Kai Lee Lo
NPI 1306065479
$2,203.85
in general payments reported to CMS, 2019-2025
48 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $271 · 2021: $42.61 · 2022: $268 · 2023: $251 · 2024: $139 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $804.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $268.64 | 2019-2025 | Optune Lua (Novottf-200t) |
| Elekta, INC. | $189.23 | 2022-2025 | |
| Amgen INC. | $162.81 | 2019-2023 | Lumakras |
| Merck Sharp & Dohme LLC | $130.55 | 2019-2023 | Lynparza, Keytruda |
| Astrazeneca Pharmaceuticals LP | $103.14 | 2019-2023 | Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $101.06 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.80 | 2019-2024 | Iclusig, Ninlaro |
| Janssen Biotech, INC. | $65.00 | 2019-2024 | Akeega, Balversa, Erleada |
| Genzyme Corporation | $64.93 | 2019-2022 | |
| Glaxosmithkline, LLC. | $62.69 | 2020-2023 | Jemperli, Zejula |
| Alexion Pharmaceuticals, INC. | $60.68 | 2019-2024 | Ultomiris |
| Lilly USA, LLC | $57.81 | 2019-2023 | Verzenio, Retevmo, Jaypirca |
| Celgene Corporation | $52.22 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $49.89 | 2023-2025 | |
| Eisai INC. | $45.46 | 2019-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.